Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer

Mutation-targeted therapies have had a major impact on the treatment of NSCLC, even for patients with advanced disease. Methods for detecting mutations, key clinical trials of targeted therapy, and the most common toxicities of EGFR and ALK inhibition were discussed at JADPRO Live.

Detalles Bibliográficos
Autores principales: Wakelee, Heather, Waxman, Elizabeth S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2018
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333550/
Descripción
Sumario:Mutation-targeted therapies have had a major impact on the treatment of NSCLC, even for patients with advanced disease. Methods for detecting mutations, key clinical trials of targeted therapy, and the most common toxicities of EGFR and ALK inhibition were discussed at JADPRO Live.

Ejemplares similares